K 604
Alternative Names: K604Latest Information Update: 19 Aug 2015
Price :
$50 *
At a glance
- Originator Kowa Pharmaceutical
- Class
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 19 Aug 2015 No recent reports on development identified - Phase-II for Atherosclerosis in USA (PO)
- 16 Aug 2011 Kowa completes a phase II trial in Atherosclerosis in USA (NCT00851500)
- 13 Jun 2008 Phase I development is ongoing